COSMOS Pharmaceutical Corporation (3349.T)

Revenue growth 1.25-1.5x 3141.T's 3.66%. Bruce Berkowitz would check if differentiation or pricing power justifies outperformance.

Both companies show negative EBIT growth. Martin Whitman would consider macro or sector-specific headwinds.

Positive net income growth while 3141.T is negative. John Neff might see a big relative performance advantage.

Positive EPS growth while 3141.T is negative. John Neff might see a significant comparative advantage in per-share earnings dynamics.

Positive diluted EPS growth while 3141.T is negative. John Neff might view this as a strong relative advantage in controlling dilution.

Share reduction while 3141.T is at 4.59%. Joel Greenblatt would see if the company has a better buyback policy than the competitor.

Reduced diluted shares while 3141.T is at 4.64%. Joel Greenblatt would see a relative advantage if the competitor is diluting more.

Dividend growth of 15.38% while 3141.T is flat. Bruce Berkowitz would see if this can become a bigger advantage long term.

10Y revenue/share CAGR 1.25-1.5x 3141.T's 110.72%. Bruce Berkowitz would investigate brand strength or geographical expansion fueling growth.

3Y revenue/share CAGR above 1.5x 3141.T's 18.55%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.

Positive 10Y CAGR while 3141.T is negative. John Neff might see a substantial advantage in bottom-line trajectory.

Positive 5Y CAGR while 3141.T is negative. John Neff might view this as a strong mid-term relative advantage.

Positive short-term CAGR while 3141.T is negative. John Neff would see a clear advantage in near-term profit trajectory.

10Y equity/share CAGR above 1.5x 3141.T's 129.53%. David Dodd would confirm if consistent earnings retention or fewer write-downs drive this advantage.

5Y equity/share CAGR above 1.5x 3141.T's 47.85%. David Dodd might see stronger earnings retention or fewer asset impairments fueling growth.

3Y equity/share CAGR above 1.5x 3141.T's 18.20%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.

10Y dividend/share CAGR above 1.5x 3141.T's 227.27%. David Dodd checks if the firm's robust cash flows justify outpacing the competitor's increases.

5Y dividend/share CAGR above 1.5x 3141.T's 33.33%. David Dodd checks if the firm's mid-term cash flows justify a faster dividend growth rate.

3Y dividend/share CAGR above 1.5x 3141.T's 20.00%. David Dodd sees a superior short-term capital return strategy if supported by stable earnings.

Our AR growth while 3141.T is cutting. John Neff questions if the competitor outperforms in collections or if we’re pushing credit to maintain sales.

We show growth while 3141.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.

Positive asset growth while 3141.T is shrinking. John Neff sees potential for us to outgrow the competitor if returns are solid.

Positive BV/share change while 3141.T is negative. John Neff sees a clear edge over a competitor losing equity.

We have some new debt while 3141.T reduces theirs. John Neff sees the competitor as more cautious unless our expansions pay off strongly.

No Data available this quarter, please select a different quarter.

We expand SG&A while 3141.T cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.